Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.1% Following Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 2.1% on Thursday after an insider sold shares in the company. The stock traded as low as $5.95 and last traded at $6.02. Approximately 1,935,999 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 5,807,483 shares. The stock had previously closed at $6.15.

Specifically, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total value of $94,800.00. Following the completion of the sale, the chief financial officer now owns 1,426,506 shares in the company, valued at $9,015,517.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total transaction of $123,200.00. Following the sale, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,697,960.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analysts Set New Price Targets

Several analysts have weighed in on RXRX shares. Jefferies Financial Group lowered their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Finally, KeyCorp dropped their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Price Performance

The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -4.14 and a beta of 0.80. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The company’s 50 day simple moving average is $6.69 and its 200-day simple moving average is $7.90.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. During the same quarter last year, the business posted ($0.38) EPS. The firm’s revenue was up 30.9% compared to the same quarter last year. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of RXRX. Mubadala Investment Co PJSC acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $128,041,000. Perceptive Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the second quarter valued at about $5,769,000. Capstone Investment Advisors LLC acquired a new stake in Recursion Pharmaceuticals during the first quarter worth about $161,000. Scientech Research LLC purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth about $1,052,000. Finally, Benjamin F. Edwards & Company Inc. lifted its stake in shares of Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after purchasing an additional 167,302 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.